Antibody Discovery Market Size To Rise USD 17.02 Bn By 2032

Published Date : 07 Dec 2023

The global antibody discovery market size is estimated at USD 6.9 billion in 2022 and is expected to reach USD 17.02 billion by 2032, growing at a CAGR of 9.5% during the forecast period.

Antibody Discovery Market Size and Growth Rate From 2023 To 2032

Market Overview

Antibodies are the proteins produced by the immune system that are capable of binding to specific foreign substances in the body, such as viruses, and destroy them. Antibody discovery is the process of identifying new therapeutic antibodies to treat diseases such as cancers, autoimmune diseases, genetic diseases, HIV, tuberculosis, and other infectious diseases.

The antibody discovery market is driven by several factors, including an increasing number of clinical trials, growing prevalence of chronic diseases, rising healthcare expenditure, health concerns, population size, advancement in research and development activities, rising adoption of advanced technologies, increasing approval of drugs, growing geriatric population, and rising demand for personalized medicine.

Innovative techniques, including phage display and hybridoma technology, are most widely used for antibody discovery. The antibody discovery process plays a crucial role in the development of new vaccines, drugs, and other therapeutic applications by permitting researchers to create certain antibodies that can recognize and target specific antigens.

The market is also rapidly revolutionizing the biotechnology and pharmaceutical industries. It encompasses various advanced technologies to identify and develop antibodies for therapeutic, diagnostic, and research applications. Prominent market players include biotechnology companies, contract research organizations (CROs), and academic institutions, all focusing on creating novel antibodies that target specific diseases. Combined with the surge in disease prevalence, this is expected to fuel the market’s growth during the forecast period.

  • In January 2023, Lotte Biologics announced the investment plan to leap forward as a global contract development and manufacturing organization (CDMO). The company plans to invest USD 3 billion by 2030 to construct three mega plants in Korea with a production capacity of 360,000 liters of antibody drugs.
  • In February 2023, The European Investment Bank (EIB) signed an agreement to invest €18 million in Icosagen AS to support its financing production facility and strengthen its innovative platforms for research and development. The European Commission's InvestEU program backs EIB's financing. The total investment in the project exceeds €40 million and is projected to begin Estonia's biological drug industry.
  • In February 2022, Piramal Pharma Solutions disclosed its plans to invest USD 75 million in its facilities in the United Kingdom. The CDMO hopes to invest in new active pharmaceutical ingredient (API) infrastructure at its Morpeth facility in England and expand the capabilities of its antibody-drug conjugate (ADC) facility in Grangemouth.
  • In October 2023, Bayer AG signed an agreement with Twist Bioscience Corporation. The collaboration allowed antibody discovery, options, and licenses to accelerate the drug discovery process.

Regional Insights

North America is expected to dominate the market during the forecast period owing to the sophisticated healthcare infrastructure, increasing investment in research and development activities, rise in healthcare investment, growing interest in advanced antibody discovery platforms, rapid adoption of AI-driven antibody drug discovery, and the increasing incidence of chronic diseases such as cancer, HIV, autoimmune disorders, and inflammatory conditions.

The United States holds the largest market share in the region. The growth of the market in the U.S. is driven by the presence of prominent market players, increasing outsourcing in the pharmaceutical industry, advancement in technology, availability of skilled workforce, robust focus on healthcare innovation, increasing awareness programs for early diagnosis, and the rise of personalized medicine which has created the demand for tailored antibody therapies.

Due to the rise in chronic disease prevalence, antibodies are widely used as therapeutics for various diseases. Monoclonal antibodies, in particular, have significant attention in the United States. As per the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. have a chronic disease, and 4 in 10 adults have two or more chronic diseases. Therefore, increasing cases of chronic diseases in the country are projected to fuel the antibody discovery market’s expansion in the coming years.

Antibody Discovery Market Report Scope:

Report Coverage Details
Market Revenue in 2023 USD 7.52 Billion
Projected Forecast Revenue by 2032 USD 17.02 Billion
Growth Rate from 2023 to 2032 CAGR of 9.5%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Market Dynamics

Drivers

An increasing number of cancer case

The rising prevalence of cancer globally has led to the increasing development of research and developments for the rapid detection, diagnosis, and treatment of the disease. As per the European Commission’s estimates published in the European Cancer Information System (ECIS), compared to 2020, new cancer cases rose by 2.3% to reach 2.74 million in 2022. Also, cancer deaths increased by 2.4% compared to 2020.

Antibody engineering offers an informed opinion on the likely evolution of the diagnosis and immunotherapy for developing the treatment of a wide range of diseases, especially cancer therapy. Therefore, with increasing cancer cases, the antibody discovery market is anticipated to grow faster in the coming years.

Increasing adoption of antibody-based therapies

The rapid adoption of antibody-based therapies for various diseases has increased the need for antibodies, which is projected to boost the antibody discovery market. Currently, over 100 monoclonal antibodies are designated as drugs or effective therapeutic agents. Due to their specificity and affinity for various molecular targets, the treatment for various chronic illnesses or diseases uses antibodies, making them indispensable tools in research. They are also the fastest-growing class of biotherapeutics in the market.

Restraint

High cost

The global Antibody Discovery market’s expansion is anticipated to be constrained by the high cost associated with the antibody discovery process. The high cost involved in the research and development of antibodies limits the market growth, which acts as a significant restraint for the market’s growth.

Opportunities

Robust growth of the biopharmaceutical industry

The rapid growth of the biopharmaceutical industry is expected to offer a lucrative opportunity for market growth during the forecast period. The continuous investment in research and development by pharmaceutical and biotechnology companies contributes to the market’s growth. The growth of the biopharmaceutical industry, coupled with the rising number of biologics in development to fight against chronic disorders, also impacts the market positively. In addition, the increasing awareness of personalized medicine and rising focus on developing antibodies tailored to individual patient characteristics has increased the demand for tailored antibody therapies. Thereby driving the market’s growth.

Technological advancements & collaboration

Biopharmaceutical and pharmaceutical companies leveraging advanced technologies to develop more effective and better-targeted drugs. The growth of the antibody discovery market is also driven by technology advancements such as high-throughput screening and artificial intelligence (AI), which help accelerate the antibody discovery processes. In addition, increasing collaborations among key market players is positively influencing the market’s expansion.

Recent Developments

  • In June 2023, AbTherx, Inc., a private biotech company, announced the launch of its next-generation human antibody discovery platform. The company is progressively accelerating antibody discovery using its novel technologies.
  • In October 2023, Hummingbird Bioscience), a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines, and Endeavor BioMedicines, a clinical-stage company targeting the drivers of fibrosis and oncology, announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio's antibody-drug conjugate (ADC), HMBD-501.
  • In Jan 2022, Ono Pharmaceutical Co., Ltd. expanded its drug discovery partnership with Neuroimmune AG. The collaboration is focused on creating antibody drugs against new therapeutic targets in neurodegenerative diseases using Neurimmune's proprietary Reverse Translational MedicineTM ("RTMTM") technology platform, a unique antibody-drug creation approach.
  • In September 2023, Ono Pharmaceutical Co., Ltd. entered into a drug discovery collaboration agreement with Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, to discover and develop innovative antibody drugs in the field of oncology. Such effective collaboration is expected to offer a lucrative opportunity for the market’s expansion during the forecast period.

Major Key Players

  • Danaher Corporation
  • Eurofins Scientific
  • Evotec
  • Twist Bioscience
  • Charles River Laboratories
  • Genscript Technology Corporation
  • Biocytogen
  • Sartorius AG
  • Fairjourney Biologics S.A
  • Creative Biolabs

Market Segmentation

By Methods

  • Phage Display
  • Hybridoma
  • Others

By Antibody Type

  • Humanized Antibody
  • Human Antibody
  • Chimeric Antibody
  • Murine Antibody

By End Users

  • Pharmaceutical and Biotechnology industry
  • Research laboratory
  • Academic laboratory

Buy this Research Report@ https://www.precedenceresearch.com/checkout/3402

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308